Cardio Diagnostics Holdings Inc. CDIO Archives

TuesdayJun 30, 2026 1:48 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management. “The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from…

MondayJun 29, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution. When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It's an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests…

FridayJun 26, 2026 12:00 pm

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings…

WednesdayJun 24, 2026 9:40 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning. Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…

WednesdayJun 17, 2026 3:26 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a broader shift taking place across the healthcare industry toward predictive and precision medicine. Cardio Diagnostics envisions a healthcare system where every patient receives individualized care informed by their unique molecular insights and where heart disease is no longer the world’s leading killer. Achieving that goal…

TuesdayJun 16, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs

Cardiovascular disease remains one of the most expensive health conditions in the United States. Cardio Diagnostics announced plans to participate in four national benefits conferences during June. The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for…

FridayJun 12, 2026 2:35 pm

QualityStocksNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (‘AI’), epigenetics and genetics to improve cardiovascular disease prevention, detection and management… The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen…

WednesdayMay 27, 2026 9:30 am

QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes. To view the full press release, visit https://ibn.fm/qFRHu About Cardio Diagnostics Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes…

MondayMay 18, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is Focused on Vision for Personalized Heart Care

CDIO’s vision reflects a broader shift taking place across the healthcare industry toward predictive and Precision Medicine. Achieving that goal requires a combination of scientific expertise, advanced technology, scalable testing and improved accessibility. Cardio Diagnostics’ focus on innovation is particularly relevant in cardiovascular disease, where earlier identification of risk factors can significantly influence outcomes. Heart disease remains the leading cause of death worldwide, yet much of modern healthcare still focuses on reacting to cardiovascular events after they occur rather than identifying risk earlier and preventing disease progression. Cardio Diagnostics Holdings (NASDAQ: CDIO) is working to help reshape that paradigm through a vision…

Site Search

Company Search

Tag: Cardio Diagnostics Holdings Inc. CDIO